Back to Clinical Feed
Try:
PLOS ONEResearch HighlightsOpen Access
Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma
25 Jun 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
- by Marta Majewska, Mateusz A. Maździarz, Ewa Lepiarczyk, Aleksandra Lipka, Marta Wiszpolska, Beata Moczulska, Elżbieta Łopieńska-Biernat, Piotr Iwanowicz, Piotr Kocbach, Hilde Galtung, Leszek Gromadziński Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a major global health challenge, characterised by a heterogeneous clinical spectrum.
- While metabolomic studies have identified disruptions in amino acid, lipid, nucleotide, and energy metabolism during COVID-19, these investigations often lack fine-grained clinical stratification. In this study, we performed untargeted metabolomic profiling of plasma from 25 participants, including five healthy controls and twenty COVID-19 patients classified into four severity groups (COV1–COV4) based on pulmonary involvement and the need for respiratory support.
- Using ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS), 541 metabolites were detected and analysed across all samples. Principal component analysis revealed a progressive metabolic divergence corresponding to disease severity.
- Monocarboxylic acid dysregulation was predominant in early to moderate cases (COV1–COV3), whereas severe disease (COV4) demonstrated a shift toward pyrimidine metabolism enrichment, consistent with heightened nucleotide turnover driven by viral replication and immune cell proliferation.
Clinical Editorial
Summary
PLOS ONE (Medicine) published a clinical update in Research Highlights on 25 Jun 2026.
The item focuses on Severity-dependent metabolic rewiring in COVID-19 based on untargeted metabolomic profiling of patient plasma.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.
Related by Condition/Drug
BMJ OpenRelated by Conditioncovid-19
Disrupted variance in respiratory illness presentation patterns in New Zealand primary care through and after the SARS-CoV-2 pandemic: an observational cohort study using automated mining of electronic health records and clinical text
Research Highlights • 25 Jun 2026
BMJ OpenRelated by Conditioncovid-19
Inequities in primary care respiratory illness presentations in Aotearoa (New Zealand) before, during and after the COVID-19 pandemic: a retrospective cohort study using automated health record analysis
Research Highlights • 25 Jun 2026
PLOS ONERelated by Conditioncovid-19
Demonstrating conservation impacts in California Marine Protected Areas using large-scale participatory science data
Research Highlights • 25 Jun 2026
NatureRelated by Conditioncovid-19
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial
Research Highlights • 25 Jun 2026
PLOS MedRelated by Conditioncovid-19
Comparisons of core component delivery in cardiac rehabilitation programs by country income classification and decade based on the 2025 Global Audit Update: A survey study
Research Highlights • 23 Jun 2026
PLOS ONERelated by Conditioncovid-19
A study protocol for mixed-methods evaluation of the structure, design, and availability of medical student wellbeing programs
Research Highlights • 18 Jun 2026
Feed Metadata
Source
PLOS ONE (Medicine)
Category
Research Highlights
Published
25 Jun 2026
Feed Metadata
Source
PLOS ONE (Medicine)
Category
Research Highlights
Published
25 Jun 2026